1-3 of 3
Natasha K. Kekre
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Michael Dickinson, Javier L. Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S Ujjani, Yi Lin, Peter A. Riedell, Natasha K. Kekre, Sven de Vos, Christine Lui, Jacob Wulff, Chad M. Williams, Weixin Peng, Ioana Kloos, Hairong Xu, Sattva S. Neelapu
Journal: Blood
Blood (2023) 142 (Supplement 1): 894.
https://doi.org/10.1182/blood-2023-174510
Published: 2023
Journal Articles

CAR-T Therapy for the Treatment of Relapsed/Refractory CD19 Positive Large B Cell Lymphoma: Canadian Real-World Evidence

Xiu Xia Sherry Tan, Melissa Maltez, Ranjeeta Mallick, Linda Hamelin, Sheryl McDiarmid, Michael Kennah, Harold Atkins, Natasha K. Kekre
Journal: Blood
Blood (2023) 142 (Supplement 1): 6923.
https://doi.org/10.1182/blood-2023-179044
Published: 2023
Journal Articles

Favorable Outcomes with Low Dose Anti Thymocyte Globulin Based Graft Versus Host Disease Prophylaxis after Mismatched Unrelated Donor Allogenic Hematopoietic Cell Transplantation

Hafsah Chalchal, Vinita Dhir, Kalina Abrol, Michelle Boyce, Michelle Delbaere, Ashish Masurekar, Mike Kennah, Natasha K. Kekre, Harold Atkins, Christopher Bredeson, David S. Allan, Ram Vasudevan Nampoothiri
Journal: Blood
Blood (2023) 142 (Supplement 1): 7002.
https://doi.org/10.1182/blood-2023-182274
Published: 2023